placebo + pregabalin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia
Conditions
Neuralgia, Spinal Cord Injuries
Trial Timeline
Jan 1, 2007 → Feb 1, 2011
NCT ID
NCT00407745About placebo + pregabalin
placebo + pregabalin is a phase 3 stage product being developed by Pfizer for Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT00407745. Target conditions include Neuralgia, Spinal Cord Injuries.
What happened to similar drugs?
8 of 17 similar drugs in Neuralgia were approved
Approved (8) Terminated (3) Active (7)
🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00905437 | Phase 3 | Terminated |
| NCT00830167 | Phase 3 | Completed |
| NCT00437281 | Phase 1/2 | Completed |
| NCT00407745 | Phase 3 | Completed |
Competing Products
20 competing products in Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 26 |
| QUTENZA | Astellas Pharma | Approved | 43 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 35 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2/3 | 38 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Galcanezumab | Eli Lilly | Approved | 43 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 35 |
| MK-8291 + Placebo | Merck | Phase 1 | 29 |
| Etoricoxib + Placebo | Merck | Approved | 39 |
| Cetuximab + Placebo | Merck | Phase 2 | 35 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 27 |
| MK0759 | Merck | Phase 2 | 27 |
| MK0686 | Merck | Phase 2 | 27 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 29 |
| EMA401 + Placebo | Novartis | Phase 2 | 27 |
| pregabalin | Pfizer | Approved | 43 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 43 |